Literature DB >> 24160800

Outcomes of vascular resection in pancreaticoduodenectomy: single-surgeon experience.

Vijay G Menon1, Vichin C Puri, Alagappan A Annamalai, Richard Tuli, Nicholas N Nissen.   

Abstract

Extension of pancreatic adenocarcinoma into adjacent vasculature often necessitates resection of the portal vein (PV) and/or superior mesenteric vein (SMV) during pancreaticoduodenectomy (PD). The vein is reconstructed primarily by end-to-end anastomosis of vein remnants or venoplasty or by use of autologous or synthetic vein grafts. The objective of this study was to review outcomes in patients undergoing PD for pancreatic adenocarcinoma, specifically comparing the short- and long-term outcomes between the patients undergoing vascular resection and those undergoing standard PD. All patients undergoing PD for pancreatic adenocarcinoma by a single surgeon between 2007 and 2012 were reviewed. Of the 61 patients identified, 18 patients underwent vascular resection of the PV (four patients), SMV (10 patients), or both (four patients). The remaining 43 patients had standard PD. Demographic, perioperative, pathological, and long-term outcomes data were collected and both vascular and standard groups were compared. Both groups had similar demographics. The vascular group had significantly longer operative times (529 vs 406 minutes; P < 0.01) with a trend to greater estimated blood loss (0.64 vs 0.53 L; P = 0.06). Pathological analysis showed no difference between the two groups with regard to lymph node status/ratio and rate of R0 resection (94 vs 91%; P = 0.57); however, the size of the tumor was significantly greater in the vascular group (4.2 vs 3 cm; P < 0.01). Short-term outcomes were similar in the vascular group and standard group, respectively, with no difference in pancreatic fistula rate (6 vs 7%; P = 1.0), transfusion rate (44 vs 35%; P = 0.57), and median length of stay (8 vs 7 days; P = 0.10), and there was no 30-day mortality in either group. Based on Kaplan-Meier methods, the median recurrence-free survival was 18 versus 23 months (P = 0.37) in the vascular and standard groups, respectively, and the overall survival was almost identical in both groups, each with a median of 31 months (P = 0.91). In our experience, mesenteric and PV resection during PD was performed safely and without compromise of short- or longer-term outcomes. It can be performed safely and patients have no significant difference in perioperative outcomes or overall survival.

Entities:  

Mesh:

Year:  2013        PMID: 24160800

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  5 in total

1.  Surgical, survival, and oncological outcomes after vascular resection in robotic and open pancreaticoduodenectomy.

Authors:  Bor-Uei Shyr; Shih-Chin Chen; Yi-Ming Shyr; Shin-E Wang
Journal:  Surg Endosc       Date:  2019-04-08       Impact factor: 4.584

2.  Comparative analysis of autologous blood transfusion and allogeneic blood transfusion in surgical patients.

Authors:  Miao-Yun Long; Zhong-Han Liu; Jian-Guang Zhu
Journal:  Int J Clin Exp Med       Date:  2014-09-15

3.  Predictors and outcomes of converted minimally invasive pancreaticoduodenectomy: a propensity score matched analysis.

Authors:  Caitlin A Hester; Ibrahim Nassour; Alana Christie; Mathew M Augustine; John C Mansour; Patricio M Polanco; Matthew R Porembka; Thomas H Shoultz; Sam C Wang; Adam C Yopp; Herbert J Zeh; Rebecca M Minter
Journal:  Surg Endosc       Date:  2019-04-23       Impact factor: 4.584

4.  A Graded Evaluation of Outcomes Following Pancreaticoduodenectomy with Major Vascular Resection in Pancreatic Cancer.

Authors:  Olga Kantor; Mark S Talamonti; Susan J Stocker; Chi-Hsiung Wang; David J Winchester; David J Bentrem; Richard A Prinz; Marshall S Baker
Journal:  J Gastrointest Surg       Date:  2016-02       Impact factor: 3.452

5.  Survival outcomes of pancreaticoduodenectomy versus extended pancreaticoduodenectomy procedure for pancreatic head carcinoma: a propensity score matching study.

Authors:  Ning Pu; Sucheng Mu; Yuan Fang; Hanlin Yin; Gao Liu; Guochao Zhao; Lei Zhang; Wenchuan Wu; Wenhui Lou
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.